RefleXion Showcases Pioneering Multi-Target Treatment (MTT) and Early Clinical Highlights at ASTRO

HAYWARD, Calif.--(BUSINESS WIRE)--Sep 26, 2024--

RefleXion ® Medical, an external-beam theranostic oncology company, today announced it will showcase Multi-target Treatment (MTT), the groundbreaking upgrade for its RefleXion® X1 platform. This innovation allows physicians to combine SCINTIX® biology-guided radiotherapy with conventional stereotactic body radiotherapy (SBRT) in a single plan to treat patients with metastatic disease. The company will also highlight learnings from its early patient treatments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240926318125/en/

Sean Shirvani, M.D., chief medical officer at RefleXion. The company will showcase its groundbreaking upgrade for the RefleXion® X1 platform, Multi-target Treatment (MTT), at ASTRO 2024. Researchers will present new scientific evidence in 22 presentations, including four oral presentations showcasing the X1 machine with SCINTIX® therapy. (Photo: Business Wire)

RefleXion will showcase MTT at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Sept. 29 – Oct. 3, in Washington D.C. (booth #1313), where researchers will present new scientific evidence in 22 presentations, including four oral presentations, showcasing the X1 machine with SCINTIX therapy.

“The results from our first-year patient treatments are highly encouraging,” said Sean Shirvani, M.D., M.P.H., chief medical officer at RefleXion. “We are consistently observing that SCINTIX therapy detects and adapts to tumor motion in an autonomous fashion. In the lung, this means that less normal lung tissue is damaged by the ablative zone of radiotherapy. And in the bone, our system provides insurance against unanticipated shifts by the patient when the radiotherapy beam is on.

“Moreover, our clinical partners recognize the immense value of having positron emission tomography or PET data underpinning both treatment planning and delivery. This information has, in several cases, influenced the course of patient therapy,” continued Shirvani.

The RefleXion X1 with SCINTIX therapy uses information from an injected PET radiopharmaceutical produced by the cancer itself in real time to determine where to deliver radiation. Because PET data is used to direct treatment, it is also an integral part of the treatment planning process.

In early SCINTIX therapy cases, PET data during treatment planning or delivery demonstrated tumor progression, uncovered additional tumors, or confirmed significant tumor movement in bone tumors, which are generally considered relatively immobile. In the bone tumor cases, SCINTIX technology accurately followed the live PET signal and delivered the dose as planned, a feat not achievable with conventional image-guided radiotherapy.

The following oral presentations highlight some of the new research being presented at ASTRO 2024. Detailed information on all 22 presentations may be found here.

• Sunday, Sept. 29, 3:37 pm, room 147 – Scientific Development and Clinical Deployment of BgRT
• Monday, Sept. 30, 3:00 pm, room 145 – Early Clinical Insights into FDG-Guided Radiotherapy Planning and Delivery on a Novel PET-Linac Platform in Patients with Lung and Bone Lesions: Pioneering Real-Time Biology-guided Radiotherapy
• Monday, Sept. 30, 3:50 pm, room 145 – Feasibility of Biology-guided Radiotherapy with Gallium-68 PSMA-11 Radiotracer for Bony Metastases in Prostate Cancer Patients
• Tuesday, Oct. 1, 8:40 am, room 152 – Impact of Synthetic PET Evaluation Prior to PET-Guided Functional Modeling in OptimizingPatient Selection for Biology-guided Radiotherapy

RefleXion’s booth will feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.

About RefleXion Medical

RefleXion is a privately held external-beam theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers that have each been assessed with onboard PET/CT prior to delivery to ensure adherence to X1 requirements for SCINTIX delivery. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240926318125/en/

CONTACT: Amy Cook

acook@reflexion.com

Media Resources

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH HOSPITALS RADIOLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: RefleXion Medical

Copyright Business Wire 2024.

PUB: 09/26/2024 09:01 AM/DISC: 09/26/2024 09:03 AM

http://www.businesswire.com/news/home/20240926318125/en